Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 20Carcinoma, Renal Cell 11Prostatic Neoplasms 8Uveal Melanoma 7Carcinoma, Non-Small-Cell Lung 7Neoplasm Metastasis 5Myelodysplastic Syndromes 5Clear-cell metastatic renal cell carcinoma 5Triple Negative Breast Neoplasms 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Brain Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Multiple Myeloma 3Hematologic Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2

Interventions

Radiotherapy 9Doxorubicin 7pazopanib 5palbociclib 4Trabectedin 4Gemcitabine 4ribociclib 3pembrolizumab 3eribulin 3Magnetic Resonance Spectroscopy 3selinexor 2liposomal doxorubicin 2avelumab 2abemaciclib 2Sunitinib 2Radiation Dose Hypofractionation 2Radiation 2Immunoglobulin G 2Ifosfamide 2Docetaxel 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zimberelimab 1temsirolimus 1sotigalimab 1sodium thiosulfate 1sitravatinib 1silmitasertib 1sargramostim 1romidepsin 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Liposarcoma × CTLA-4 Antigen × Clear all
NCT03307616 2026-03-05

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
32 enrolled
Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡